Suven Life Sciences Experiences Revision in Stock Evaluation Amid Strong Market Performance
Suven Life Sciences has experienced a notable adjustment in its evaluation, reflecting its recent stock performance. The company, a smallcap player in the pharmaceutical sector, has outperformed both its industry and the broader market, indicating strong growth potential. Additionally, it has been added to MarketsMojo's list, highlighting its promising trajectory.
Suven Life Sciences, a smallcap player in the pharmaceutical sector, has recently experienced a notable shift in its stock evaluation. Following a robust performance that saw its stock price increase by 7.3% on December 6th, 2024, the company has caught the attention of analysts and investors alike. This rise comes on the heels of a strong market showing, where Suven Life Sciences outperformed its sector by 7.36%.Despite previously receiving a 'Strong Sell' rating from MarketsMOJO, the recent uptick in stock price suggests a potential shift in sentiment. After enduring three consecutive days of declines, the stock rebounded impressively, opening lower before reaching an intraday high of Rs 143.45, marking a significant recovery.
The trading day was marked by volatility, with the stock touching an intraday low of Rs 130. However, the overall trend appears positive, as Suven Life Sciences is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This upward trajectory indicates a strengthening position in the market.
In terms of broader market performance, Suven Life Sciences has outpaced the Sensex by 7.04% over the past day and 5.65% over the past month, underscoring its competitive edge within the pharmaceutical industry.
Given these developments, MarketsMOJO has added Suven Life Sciences to its list, reflecting a revision in its score that aligns with the company's recent performance metrics. As a smallcap entity, Suven Life Sciences continues to demonstrate resilience and potential for growth, making it a stock to monitor closely in the evolving landscape of pharmaceuticals.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
